Rajendra Pandya, MD
Infectious Disease · Houston, TXNPI 1265442420
Payments from drug & device makers
What this record shows
This record is dominated by education: $64 of the $91 with a category attached, or 70.0%. Merck accounts for 70.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $62 and has fallen 73.8% since, to $16 in 2024. That places this record below the midpoint for infectious disease clinicians in TX, where the typical reported total is $451.
Across 7 payments — averaging $12.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$64
- Shionogi Inc$16
- Paratek Pharmaceuticals, Inc.$11
Across 16 payments — averaging $12,941 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$150K
- Teva Pharmaceuticals USA, Inc.$21K
- Pfizer$20K
- Sanofi US Services Inc.$15K
What the payments were for
- Food & beverage$2730%
- Education$6470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 5 | $64 |
| Shionogi Inc | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$91 in reported general payments places this provider in the 20th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErtapenemErtapenem Sodium | 21 | $9,553 |
| Cefepime Hcl | 17 | $7,732 |
| Meropenem | 27 | $6,825 |
| Ampicillin Sodium | 21 | $6,528 |
| CeftriaxoneCeftriaxone Sodium | 23 | $1,447 |
| Rifampin | 14 | $1,116 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 19 | $541 |
| Cephalexin | 28 | $504 |
| Ciprofloxacin Hcl | 14 | $186 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $60 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Houston
- Joseph GatheHouston$695K
- Roy ChemalyHouston$686K
- Ben BarnettHouston$424K
- Amar SafdarHouston$284K
- Luis OstroskyHouston$173K
- Richard HamillHouston$137K
- Karen VigilHouston$91K
- John RexHouston$63K
- Pablo OkhuysenHouston$57K
- Rodrigo HasbunHouston$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.